AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9458824 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP infusion (1, 2, or 4 pmol.kg‐1.min‐1 for 60 min)
Number of subjects: 48
Study 8058542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous meperidine (0.8 mg/kg)
Number of subjects: 10
Study 8058542 — intervention group
Group type: EXPERIMENTAL
Intervention: Submucosal meperidine (0.8 mg/kg)
Number of subjects: 10
Study 8058542 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular meperidine (0.8 mg/kg)
Number of subjects: 10
Study 8058542 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral meperidine (1.4 mg/kg)
Number of subjects: 10
Study 2973132 — intervention group
Group type: EXPERIMENTAL
Intervention: HBM clinical intervention administered in the ED
Number of subjects: 0
Study 2973132 — intervention group
Group type: EXPERIMENTAL
Intervention: HBM phone intervention made 1 to 2 days post-ED visit
Number of subjects: 0
Study 2973132 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HBM clinical and phone interventions
Number of subjects: 0
Study 2973132 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 28847853 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic needs assessment (HNA) and care planning by an allied health professional
Number of subjects: 150
Study 28847853 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 28847853 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic needs assessment (HNA) and care planning
Number of subjects: 150
Study 28847853 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic analysis
Number of subjects: 150
Study 28786220 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 1726
Study 28786220 — intervention group
Group type: COMPARATOR
Intervention: No androgen deprivation therapy (Control)
Number of subjects: 1726
Study 27268421 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 100 mg every 4 weeks
Number of subjects: 380
Study 27268421 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks
Number of subjects: 380
Study 27268421 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 380
Study 27268421 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg once weekly
Number of subjects: 380
Study 27268421 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study 27268421 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (all doses)
Number of subjects: 380
Study 24554099 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride toothpaste (1100 µg F/g, NaF/SiO2) used three times a day
Number of subjects: 6
Study 24554099 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoride toothpaste (negative control)
Number of subjects: 6
Study 23734260 — intervention group
Group type: EXPERIMENTAL
Intervention: AF-specific management intervention
Number of subjects: 335
Study 23734260 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 335
Study 20583555 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon (an early interferon 1 and 2 inductor)
Number of subjects: 150
Study 20583555 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard symptomatic therapy with cycloferon
Number of subjects: 150
Study 19108494 — intervention group
Group type: EXPERIMENTAL
Intervention: rikkunshito (TJ‐43)
Number of subjects: 142
Study 19108494 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 142
Study 16632141 — intervention group
Group type: COMPARATOR
Intervention: Telephone interview
Number of subjects: 416
Study 16632141 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal survey
Number of subjects: 416
Study 12818975 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 2 mg and fentanyl 12.5 micro g
Number of subjects: 60
Study 12818975 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 2 mg and fentanyl 12.5 micro g with morphine 125 micro g
Number of subjects: 60
Study 12818975 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 60
Study 11349388 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine 12.5 mg and 37.5 mg
Number of subjects: 16
Study 11349388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin 30 mg
Number of subjects: 16
Study 11349388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9203655 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified recombinant hemagglutinin (rHA) from influenza A/Beijing/32/92 (H3N2) virus
Number of subjects: 0
Study 9203655 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study 7960505 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma
Number of subjects: 10
Study 7960505 — intervention group
Group type: COMPARATOR
Intervention: Synovial fluid
Number of subjects: 10
Study 2958914 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.08 mg ipratropium bromide
Number of subjects: 64
Study 2958914 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mg ipratropium bromide
Number of subjects: 64
Study 2958914 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg ipratropium bromide
Number of subjects: 64
Study 29940902 — intervention group
Group type: EXPERIMENTAL
Intervention: Thirsty? Choose Water! behavioural intervention (TCW‐BI)
Number of subjects: 60
Study 29940902 — intervention group
Group type: EXPERIMENTAL
Intervention: Chilled water stations
Number of subjects: 60
Study 29940902 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TCW‐BI and chilled water stations
Number of subjects: 60
Study 29940902 — intervention group
Group type: COMPARATOR
Intervention: Neither intervention (control group)
Number of subjects: 60
Study 28033030 — intervention group
Group type: EXPERIMENTAL
Intervention: IVI and KIN
Number of subjects: 56
Study 28033030 — intervention group
Group type: COMPARATOR
Intervention: IVI
Number of subjects: 56
Study 28033030 — intervention group
Group type: COMPARATOR
Intervention: Math control group
Number of subjects: 56
Study 26454386 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey dressing (group A)
Number of subjects: 348
Study 26454386 — intervention group
Group type: COMPARATOR
Intervention: Normal saline dressing (group B)
Number of subjects: 348
Study 23293008 — intervention group
Group type: EXPERIMENTAL
Intervention: 14°C Cold-Water Immersion (CWI)
Number of subjects: 12
Study 23293008 — intervention group
Group type: EXPERIMENTAL
Intervention: 30°C Warm-Water Immersion (WWI)
Number of subjects: 12
Study 23293008 — intervention group
Group type: COMPARATOR
Intervention: Passive Control (CON)
Number of subjects: 12
Study 21641198 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 IU of oxytocin infused over 30 min (0.33 IU/min) - G1
Number of subjects: 30
Study 21641198 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 IU of oxytocin infused over 3 min and 45 s (2.67 IU/min) - G2
Number of subjects: 30
Study 21641198 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 IU of oxytocin infused over 30 min (2.67 IU/min) - G3
Number of subjects: 30
Study 18815568 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (n = 11) performed three sets of three-repetition maximum bench presses before throwing
Number of subjects: 23
Study 18815568 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12) rested passively for 15 minutes before throwing
Number of subjects: 23
Study 16466322 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 32
Study 16466322 — intervention group
Group type: COMPARATOR
Intervention: Control groups from randomized controlled trials
Number of subjects: 32
Study 16466322 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized controlled trial assessing propranolol
Number of subjects: 32
Study 14728498 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless PDA software for pre-operative patient assessment
Number of subjects: 0
Study 14728498 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard assessment without PDA)
Number of subjects: 0
Study 11191538 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive pressure support ventilation (NIPSV)
Number of subjects: 40
Study 11191538 — intervention group
Group type: COMPARATOR
Intervention: Conventional oxygen therapy
Number of subjects: 40
Study 9169309 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 256
Study 9169309 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 256
Study 31113857 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive Spirometry (IS)
Number of subjects: 112
Study 31113857 — intervention group
Group type: COMPARATOR
Intervention: EzPAP lung expansion therapy
Number of subjects: 112
Study 31113857 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IS and EzPAP
Number of subjects: 112
Study 29248711 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival augmentation using CTG (group IIb)
Number of subjects: 57
Study 29248711 — intervention group
Group type: EXPERIMENTAL
Intervention: Gingival augmentation using CMX (group IIIb)
Number of subjects: 57
Study 29248711 — intervention group
Group type: COMPARATOR
Intervention: Control group I (without GA)
Number of subjects: 57
Study 26785092 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training using live feline model
Number of subjects: 171
Study 26785092 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training using simulated feline model
Number of subjects: 171
Study 26785092 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraining assessment at 18 weeks
Number of subjects: 171
Study 26785092 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraining assessment at 52 weeks
Number of subjects: 171
Study 26785092 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience level in performing pediatric and neonatal intubation
Number of subjects: 171
Study 24660840 — intervention group
Group type: EXPERIMENTAL
Intervention: RPV+FTC/TDF
Number of subjects: 543
Study 24660840 — intervention group
Group type: COMPARATOR
Intervention: EFV+FTC/TDF
Number of subjects: 543
Study 22526198 — intervention group
Group type: EXPERIMENTAL
Intervention: Taping
Number of subjects: 18
Study 22526198 — intervention group
Group type: COMPARATOR
Intervention: Cylinder cast immobilization
Number of subjects: 18
Study 19274698 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-combination (butterbur root, valerian root, passionflower herb, lemon balm leaf)
Number of subjects: 182
Study 19274698 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-combination (valerian root, passionflower herb, lemon balm leaf)
Number of subjects: 182
Study 19274698 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 16857467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous hydromorphone at 0.015 mg/kg
Number of subjects: 198
Study 16857467 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine at 0.1 mg/kg
Number of subjects: 198
Study 15537997 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotherapy (20 min of water exercises at 71 degrees F, full immersion, 3 times per week)
Number of subjects: 20
Study 15537997 — intervention group
Group type: COMPARATOR
Intervention: Passive range of motion exercise and oral baclofen (control group)
Number of subjects: 20
Study 11283528 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 198
Study 11283528 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy
Number of subjects: 198
Study 9416930 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of morphine administered intravenously (group 1A)
Number of subjects: 38
Study 9416930 — intervention group
Group type: COMPARATOR
Intervention: No morphine administered (group 1B)
Number of subjects: 38
Study 8100189 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of roxatidine acetate twice daily
Number of subjects: 408
Study 8100189 — intervention group
Group type: COMPARATOR
Intervention: 150 mg of ranitidine twice daily
Number of subjects: 408
Study 2892152 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine
Number of subjects: 14
Study 2892152 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study 30598522 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline levels of miR-150
Number of subjects: 462
Study 30598522 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline levels of miR-30a-5p
Number of subjects: 462
Study 30598522 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels (T3) of miR-150
Number of subjects: 462
Study 30598522 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels (T3) of miR-30a-5p
Number of subjects: 462
Study 30598522 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels (T1) of miR-15a
Number of subjects: 462
Study 30598522 — intervention group
Group type: EXPERIMENTAL
Intervention: Low levels (T1) of miR-375
Number of subjects: 462
Study 27781435 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong beer
Number of subjects: 18
Study 27781435 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular beer
Number of subjects: 18
Study 27781435 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonalcoholic beer
Number of subjects: 18
Study 27781435 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft drink
Number of subjects: 18
Study 27781435 — intervention group
Group type: EXPERIMENTAL
Intervention: Two additional beers (MSt2)
Number of subjects: 18
Study 25899547 — intervention group
Group type: EXPERIMENTAL
Intervention: Postural stability assessment during different periods of the day (8-10 am, 10-12 am, 1 pm-3 pm, 3 pm-5 pm)
Number of subjects: 241
Study 25899547 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of diurnal variation of balance control
Number of subjects: 241
Study 25899547 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of knee pain during different periods of the day
Number of subjects: 241
Study 24402336 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% Melaleuca alternifolia essential oil
Number of subjects: 15
Study 24402336 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% triclosan
Number of subjects: 15
Study 24402336 — intervention group
Group type: COMPARATOR
Intervention: soft soap + propan‐2‐ol
Number of subjects: 15
Study 24402336 — intervention group
Group type: COMPARATOR
Intervention: soft soap
Number of subjects: 15
Study 20067963 — intervention group
Group type: EXPERIMENTAL
Intervention: READY-Girls intervention (n = 43)
Number of subjects: 88
Study 20067963 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n = 45)
Number of subjects: 88
Study 18006327 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation programme lasting 4 weeks
Number of subjects: 12
Study 18006327 — intervention group
Group type: COMPARATOR
Intervention: Postoperative outcomes
Number of subjects: 12
Study 16837890 — intervention group
Group type: EXPERIMENTAL
Intervention: Actaea or Cimicifuga racemosa extract (CR BNO 1055)
Number of subjects: 400
Study 12631634 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA and endoprosthesis placement (Hemobahn endoprosthesis, W.L. Gore & Associates)
Number of subjects: 28
Study 12631634 — intervention group
Group type: COMPARATOR
Intervention: PTA alone
Number of subjects: 28
Study 10853403 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 micrograms vaginal misoprostol pre-operatively
Number of subjects: 278
Study 10853403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278
Study 9089852 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine 10 mg
Number of subjects: 49
Study 9089852 — intervention group
Group type: EXPERIMENTAL
Intervention: morphine 0.15 mg
Number of subjects: 49
Study 9089852 — intervention group
Group type: EXPERIMENTAL
Intervention: meperidine 10 mg plus morphine 0.15 mg
Number of subjects: 49
Study 8250107 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine (25 mg/kg for 48 hr)
Number of subjects: 80
Study 8250107 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (5 mg/kg twice a day for five days)
Number of subjects: 80
Study 3513269 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized salbutamol (1 mg)
Number of subjects: 12
Study 3513269 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenbuterol (30 micrograms)
Number of subjects: 12
Study 3513269 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 ml of normal saline)
Number of subjects: 12
Study 30106527 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step 0.454% SnF₂ dentifrice followed by 3% H₂O₂ whitening gel, 1+1 minute sequential brushing (experimental)
Number of subjects: 165
Study 30106527 — intervention group
Group type: COMPARATOR
Intervention: 0.76% sodium monofluorophosphate dentifrice (Colgate Cavity Protection), twice daily use (control)
Number of subjects: 165
Study 28045865 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 50
Study 28045865 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 28045865 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study 26298036 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-Enhanced Ultrasound (CEUS)
Number of subjects: 52
Study 26298036 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonoelastography (SE)
Number of subjects: 52
Study 26298036 — intervention group
Group type: COMPARATOR
Intervention: Systematic Biopsy (SB)
Number of subjects: 52
Study 23801585 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal rotigotine 2 to 16 mg/24 hours (mean dose, 12.8 mg/24 hours)
Number of subjects: 172
Study 23801585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 21592728 — intervention group
Group type: EXPERIMENTAL
Intervention: Crestal sinus elevation using the new water lift system
Number of subjects: 50
Study 21592728 — intervention group
Group type: COMPARATOR
Intervention: Lateral sinus elevation with piezosurgery
Number of subjects: 50
Study 18837799 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (n = 20)
Number of subjects: 35
Study 18837799 — intervention group
Group type: COMPARATOR
Intervention: Weight maintenance (n = 15)
Number of subjects: 35
Study 17062959 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise segmental pulmonary vein isolation (SPVI)
Number of subjects: 110
Study 17062959 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumferential pulmonary vein isolation (CPVI)
Number of subjects: 110
Study 15648667 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcellular rubber insole footwear
Number of subjects: 0
Study 15648667 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive footwear
Number of subjects: 0
Study 10931123 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (600 mg/24 h for 2 weeks, then 900 mg/24 h for 2 weeks)
Number of subjects: 21
Study 10931123 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10931123 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 21
Study 9048676 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 year of treatment with AEDs
Number of subjects: 244
Study 9048676 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 years of treatment with AEDs
Number of subjects: 244
Study 9048676 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 244
Study 8244814 — intervention group
Group type: EXPERIMENTAL
Intervention: Palladium-103 (Pd-103) seeds
Number of subjects: 15
Study 8244814 — intervention group
Group type: COMPARATOR
Intervention: Iodine-125 (I-125) seeds
Number of subjects: 15
Study 2942844 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg twice a day
Number of subjects: 106
Study 2942844 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg once a day
Number of subjects: 106
Study 2942844 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 106
Study 31170623 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg niacin
Number of subjects: 124
Study 31170623 — intervention group
Group type: COMPARATOR
Intervention: 100 mg sugar pill (placebo)
Number of subjects: 124
Study 28517999 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (ambulated before and during hypobaric exposure)
Number of subjects: 107
Study 28517999 — intervention group
Group type: COMPARATOR
Intervention: Control (no ambulation)
Number of subjects: 107
Study 28517999 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (ambulated only before hypobaric exposure)
Number of subjects: 107
Study 25777290 — intervention group
Group type: EXPERIMENTAL
Intervention: jollab (15ml, t.i.d., four weeks, orally)
Number of subjects: 160
Study 25777290 — intervention group
Group type: COMPARATOR
Intervention: placebo (15ml, t.i.d., four weeks, orally)
Number of subjects: 160
Study 25777290 — intervention group
Group type: EXPERIMENTAL
Intervention: jollab
Number of subjects: 160
Study 25777290 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 160
Study 23125437 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency nurse-initiated intervention based on the 5A's framework (Ask-Advise-Assess-Assist-Arrange)
Number of subjects: 789
Study 23125437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention period
Number of subjects: 789
Study 23125437 — intervention group
Group type: COMPARATOR
Intervention: Preintervention period
Number of subjects: 789
Study 22073146 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (5000 IU cholecalciferol, one capsule daily for six weeks)
Number of subjects: 128
Study 20205028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (school-based intervention programme)
Number of subjects: 291
Study 20205028 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 291
Study 17911991 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 184
Study 17911991 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 184
Study 15841817 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatments scheduled every 3 months
Number of subjects: 105
Study 15841817 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatments scheduled every 6 months
Number of subjects: 105
Study 15841817 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatments scheduled every 18 months
Number of subjects: 105